Holen Sie sich die Stockscreener-App
35.89
2.57%
0.90
Schlusskurs vom Vortag:
$34.99
Offen:
$34.69
24-Stunden-Volumen:
1.18M
Relative Volume:
0.63
Marktkapitalisierung:
$2.59B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-368.95M
KGV:
-6.4721
EPS:
-5.5453
Netto-Cashflow:
$-293.81M
1W Leistung:
+4.97%
1M Leistung:
+19.83%
6M Leistung:
-9.48%
1J Leistung:
+63.88%
1-Tages-Spanne:
$34.69
$36.41
1-Wochen-Bereich:
$33.18
$36.41
52-Wochen-Spanne:
$21.96
$56.05
Vera Therapeutics Inc Stock (VERA) Company Profile
Firmenname
Vera Therapeutics Inc
Sektor
Branche
Telefon
650-770-0077
Adresse
2000 SIERRA POINT PARKWAY, SUITE 1200, BRISBANE
Compare VERA vs VRTX, REGN, ARGX, MRNA, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
VERA
Vera Therapeutics Inc
|
35.89 | 2.25B | 0 | -368.95M | -293.81M | -5.5453 |
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Vera Therapeutics Inc Stock (VERA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-11 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2025-10-16 | Eingeleitet | BofA Securities | Buy |
| 2025-08-04 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2025-05-05 | Fortgesetzt | H.C. Wainwright | Buy |
| 2025-02-04 | Eingeleitet | Wolfe Research | Outperform |
| 2025-01-28 | Eingeleitet | Goldman | Buy |
| 2024-11-21 | Eingeleitet | Wells Fargo | Overweight |
| 2024-10-16 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-01-25 | Eingeleitet | Oppenheimer | Outperform |
| 2024-01-08 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-12-18 | Eingeleitet | Raymond James | Outperform |
| 2023-11-10 | Hochstufung | Jefferies | Hold → Buy |
| 2023-08-16 | Eingeleitet | Guggenheim | Buy |
| 2023-01-04 | Herabstufung | Jefferies | Buy → Hold |
| 2023-01-04 | Herabstufung | Wedbush | Outperform → Neutral |
| 2022-07-12 | Eingeleitet | JP Morgan | Overweight |
| 2022-05-02 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-04-19 | Eingeleitet | Wedbush | Outperform |
Alle ansehen
Vera Therapeutics Inc Aktie (VERA) Neueste Nachrichten
VERA Stock Surges After Drug To Treat Rare Kidney Disease Gets FDA Approval – Retail Sees The Move As Catalyst For Vera Therapeutics - Stocktwits
Nancy Lee Boman Net Worth (2026) - GuruFocus
Vera Therapeutics (NASDAQ:VERA): What Could Drive the Next Move? - Kalkine Media
What Vera Therapeutics (VERA)'s Widening Losses and Cash Burn Mean For Shareholders - Sahm
Vera Therapeutics, Inc. (NASDAQ:VERA) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
H.C. Wainwright Maintains Vera Therapeutics(VERA.US) With Buy Rating, Cuts Target Price to $90 - Moomoo
Bank of America Corp DE Has $23.72 Million Stake in Vera Therapeutics, Inc. $VERA - MarketBeat
Vera Therapeutics upgraded to Buy after FDA nod for TRUTAKNA and positive kidney function data. - Pluang
Vera Therapeutics: FDA's eGFR Analysis Supports A Speculative Buy (NASDAQ:VERA) - Seeking Alpha
Wedbush Reiterates Neutral Rating for Vera Therapeutics (NASDAQ:VERA) - MarketBeat
J.P. Morgan Maintains Vera Therapeutics(VERA.US) With Buy Rating, Cuts Target Price to $76 - Moomoo
Vera Therapeutics Stock (VERA) Opinions on Positive eGFR Data Release - Quiver Quantitative
Vera Therapeutics Shares Up 9.7% as $425,000 Drug Launch Puts Focus on Cash Reserves - TechStock²
Vera Therapeutics Climbs as Investors React to TRUTAKNA Launch Progress and Near-Term IgAN Milestones - Quiver Quantitative
Kynam Capital (VERA) now holds 4.01% beneficial stake in Vera Therapeutics - Stock Titan
Vera Therapeutics (NASDAQ:VERA) Shares Gap UpHere's Why - MarketBeat
HC Wainwright Has Positive Estimate for VERA Q3 Earnings - MarketBeat
Vera stock rises on FDA review for kidney drug (VERA:NASDAQ) - Seeking Alpha
Is Vera Therapeutics (VERA) Undervalued On FDA Approval For TRUTAKNA? - Sahm
(VERA) Volatility Zones as Tactical Triggers - Stock Traders Daily
Vera Therapeutics president and CEO Marshall Fordyce sells $701,769 in stock - Investing.com
Vera Therapeutics president and CEO Marshall Fordyce sells $1.96m in stock - Investing.com
Vera Therapeutics CEO Marshall Fordyce sells $679,747 in stock - Investing.com
Vera Therapeutics (VERA) CEO trades 18,500 shares via 10b5-1 option exercise - Stock Titan
Vera Therapeutics (VERA) CEO option exercise and 18,500-share sale under 10b5-1 plan - Stock Titan
Goldman Sachs lowers Vera Therapeutics stock price target to $80 By Investing.com - Investing.com Nigeria
H.C. Wainwright cuts Vera Therapeutics stock price target on competition By Investing.com - Investing.com Nigeria
Vera Therapeutics (NASDAQ:VERA) Given New $90.00 Price Target at HC Wainwright - MarketBeat
H.C. Wainwright cuts Vera Therapeutics stock price target on competition - Investing.com India
E. Ohman J or Asset Management AB Acquires 42,787 Shares of Vera Therapeutics, Inc. $VERA - MarketBeat
Vera Therapeutics, Inc. Stock 12‑Month Price Target Cut to $81.21, Implies 157% Upside - TradingView
Wedbush Lowers Vera Therapeutics (NASDAQ:VERA) Price Target to $34.00 - MarketBeat
Vera Therapeutics (VERA) Stock Analysis: A Biotech With Potential 157.85% Upside - DirectorsTalk Interviews
Vera Therapeutics Provides Business Update and Reports Second Quarter 2026 Financial Results - The Manila Times
VERA SWOT Analysis: Accelerated Approval of TRUTAKNA Marks a Key Milestone - GuruFocus
Vera Therapeutics Q2 Results: Net loss widens to $109.5 million - scanx.trade
Vera Therapeutics Q2 Results: EPS beats estimates despite wider losses - scanx.trade
Vera Therapeutics Q2 loss widens less than expected - TradingView
Vera Therapeutics (NASDAQ:VERA) Announces Quarterly Earnings Results - MarketBeat
Vera Therapeutics reports Q2 net loss of $109.5M as TRUTAKNA receives FDA accelerated approval - TradingView
Vera Therapeutics (VERA) ramps spending ahead of TRUTAKNA launch and posts $230.5M loss - Stock Titan
Vera's TRUTAKNA Gets FDA Accelerated Approval for IgA Nephropathy - Stock Titan
Dimensional Fund Advisors LP Decreases Stock Position in Vera Therapeutics, Inc. $VERA - MarketBeat
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
State Street Corporation (VERA) discloses 4.1M-share stake in Vera Therapeutics - Stock Titan
The Manufacturers Life Insurance Company Cuts Stock Position in Vera Therapeutics, Inc. $VERA - MarketBeat
Equity awards for Vera Therapeutics (VERA) Chief Regulatory Officer - Stock Titan
Vera Therapeutics under pressure in first earnings since approval By Investing.com - Investing.com Canada
Vera Therapeutics names Nancy Lee Boman as chief regulatory officer in initial beneficial ownership filing - Bitget
Vera Therapeutics, Inc. (VERA) Stock Analysis: A Biotech With 153% Potential Upside - DirectorsTalk Interviews
Vera Therapeutics (NASDAQ:VERA) Stock Price Down 5.8%Here's Why - MarketBeat
Finanzdaten der Vera Therapeutics Inc-Aktie (VERA)
Umsatz
Nettogewinn
Free Cashflow
ENV
Vera Therapeutics Inc-Aktie (VERA) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Fordyce Marshall | PRESIDENT AND CEO |
Sep 02 '26 |
Sale |
35.12 |
18,500 |
649,642 |
235,244 |
0.86%
0.31%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):